Resistant Hypertension - Pipeline Review, H2 2016

  • ID: 4030249
  • Report
  • 34 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Novartis AG
  • Zumbro Discovery Inc
  • MORE
Resistant Hypertension - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension - Pipeline Review, H2 2016, provides an overview of the Resistant Hypertension (Cardiovascular) pipeline landscape.

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Resistant Hypertension - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Resistant Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Resistant Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Resistant Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Resistant Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Resistant Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Hypertension (Cardiovascular)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Resistant Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Resistant Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Novartis AG
  • Zumbro Discovery Inc
  • MORE
Introduction

Resistant Hypertension Overview

Pipeline Products for Resistant Hypertension - Overview

Resistant Hypertension - Therapeutics under Development by Companies

Resistant Hypertension - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Resistant Hypertension - Products under Development by Companies

Resistant Hypertension - Companies Involved in Therapeutics Development

Bayer AG

Novartis AG

Sarfez Pharmaceuticals Inc

PhaseBio Pharmaceuticals Inc

Zumbro Discovery Inc

Resistant Hypertension - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BAY-1636183 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHW-090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-20203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZD-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Resistant Hypertension - Dormant Projects

Resistant Hypertension - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Resistant Hypertension, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Resistant Hypertension - Pipeline by Bayer AG, H2 2016

Resistant Hypertension - Pipeline by Novartis AG, H2 2016

Resistant Hypertension - Pipeline by Sarfez Pharmaceuticals Inc, H2 2016

Resistant Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016

Resistant Hypertension - Pipeline by Zumbro Discovery Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Resistant Hypertension - Dormant Projects, H2 2016

Resistant Hypertension - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Resistant Hypertension, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Novartis AG
  • Sarfez Pharmaceuticals Inc
  • PhaseBio Pharmaceuticals Inc
  • Zumbro Discovery Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll